These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37957751)

  • 1. A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD).
    Guo P; Xu Y; Lv L; Feng M; Fang Y; Huang WQ; Cheng SF; Qian MC; Yang S; Wang SK; Chen HX
    Ann Gen Psychiatry; 2023 Nov; 22(1):46. PubMed ID: 37957751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on the Changes in Circadian Rhythm Before and After Treatment and the Influencing Factors in Patients with Depression.
    Guo P; Fang Y; Feng M; Shen Y; Yang S; Wang S; Qian M
    Neuropsychiatr Dis Treat; 2022; 18():2661-2669. PubMed ID: 36387948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
    CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM; Gao KR; Yu H; Shen YF; Li HF
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder.
    Huang J; Xie XM; Lyu N; Fu BB; Zhao Q; Zhang L; Wang G
    Front Psychiatry; 2023; 14():1115008. PubMed ID: 37151978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study.
    Urade CS; Mahakalkar SM; Tiple PG
    J Pharmacol Pharmacother; 2015; 6(4):198-203. PubMed ID: 26813706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronotype on antidepressant treatment and symptoms in patients with depression: a multicenter, parallel, controlled study.
    Wang S; Feng M; Fang Y; Lv L; Sun G; Cheng S; Huang W; Yang S; Guo P; Qian M; Chen H
    BMC Psychiatry; 2023 Apr; 23(1):277. PubMed ID: 37081401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
    Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.
    Martinotti G; Sepede G; Gambi F; Di Iorio G; De Berardis D; Di Nicola M; Onofrj M; Janiri L; Di Giannantonio M
    J Clin Psychopharmacol; 2012 Aug; 32(4):487-91. PubMed ID: 22722509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
    J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor analysis of electroacupuncture and selective serotonin reuptake inhibitors for major depressive disorder: an 8-week controlled clinical trial.
    Yang X; Gong W; Ma X; Wang S; Wang X; Guo T; Guo Z; Sun Y; Li J; Zhao B; Tu Y
    Acupunct Med; 2020 Feb; 38(1):45-52. PubMed ID: 31544488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agomelatine: An Astounding Sui-generis Antidepressant?
    Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
    Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.